Navigation Links
Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Date:3/25/2013

mmune system that help control the body's response to a foreign or harmful substance or stimuli. LIFITEGRAST is administered via a preservative-free topical eye solution.

Three clinical trials - OPUS-1, OPUS-2 and SONATA - currently make up the phase 3 clinical development program for LIFITEGRAST. OPUS-1, a safety and efficacy study, concluded in 2012. In this study the co-primary endpoint of reducing signs of dry eye was met.  Although the co-primary endpoint of reducing symptoms was not achieved, this study was the basis of a positive meeting with the FDA and for the continuation of the phase 3 clinical program, including OPUS-2, a safety and efficacy study of both signs and symptoms of dry eye disease, which is currently ongoing.  In addition to the OPUS-2 clinical efficacy study, SONATA, a randomized, placebo-controlled safety study is also ongoing.  Shire is excited about the potential contribution of this product to the treatment options for patients with dry eye disease.

About Dry Eye Disease

Dry eye disease varies in severity and etiology, and symptoms most commonly manifest as ocular discomfort, eye dryness, and tear film instability due to decreased quality or quantity of tears. A major contributing factor towards the development of dry eye is inflammation caused by T-cell infiltration, proliferation and inflammatory cytokine production that can lead to reduction in tear film quality and ocular surface damage.

Some 25 million people are affected in the United States. This number is expected to grow substantially in the next decade due to an aging population, a contributor to higher rates of dry eye disease.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of:

  • Behavioral Health a
    '/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , August 26, 2015 Israel Proves ... DiaCardio wins 1 st place  Wayerz comes in ... Israel by venture capital fund JVP, with ... the US, China , Israel ... .  Impressive achievement for the Israeli representatives in ...
(Date:8/26/2015)... Boston, MA (PRWEB) , ... August 26, 2015 , ... ... venue for Boston adult stem cell technology start-up company Asymmetrex to share ... widely the capabilities of a new biomarker for counting adult tissue stem cells. , ...
(Date:8/25/2015)... Calif. (PRWEB) , ... August 25, 2015 , ... One ... Valley -based Resilinc Corp., Bindiya Vakil, has been on a mission for ... the impact on global supply chain operations - from the two massive explosions that ...
(Date:8/25/2015)... PRUSSIA, Pa. , Aug. 25, 2015   ... has been enrolled in its Phase II/III clinical study ... company,s recombinant fusion protein linking coagulation factor VIIa with ... hemophilia A or B who have developed an inhibitor ... study will enroll approximately 54 male patients, the first ...
Breaking Biology Technology:Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 2CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 3CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 4
... Cardium Therapeutics,(NYSE: CXM ) today reported ... of Medicine showing the long-term outcome of a method ... disorder of the immune system.,The infant children studied had ... arises in infants with a genetic defect that,leaves them ...
... Shares of Common StockAt a Price of $5.00 per ... Group, Inc. (the "Company" or "PharmaNet") (Nasdaq: ... today announced that it has signed a definitive merger ... ("JLL"). Under the terms of the Merger Agreement, JLL ...
... Secondary Endpoints -- CAPACITY 1 Misses Primary Endpoint, Provides ... MAA -BRISBANE, Calif., Feb. 3 InterMune, Inc. (Nasdaq: ... two Phase 3 CAPACITY studies evaluating pirfenidone in patients ... of change in percent predicted Forced Vital Capacity (FVC) ...
Cached Biology Technology:Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 2Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 3Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 4Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 2PharmaNet Development Group Agrees to be Acquired by JLL Partners 3PharmaNet Development Group Agrees to be Acquired by JLL Partners 4PharmaNet Development Group Agrees to be Acquired by JLL Partners 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 6PharmaNet Development Group Agrees to be Acquired by JLL Partners 7InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 2InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 3InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 4InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 5InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 6InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 7InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 8InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 9InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 10InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 11
(Date:8/11/2015)... August 11, 2015 Today, ZUK announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the ... Second quarter contract revenue of $ 85.2 ... contract margins of 26 % , Second ... EPS from royalties in the current quarter , ... very pleased to present another strong financial quarter, with all our ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... PHILADELPHIA (July 30, 2012) When the longest cells in the ... repair is no easy task. This is in part because ... to one meter in adult humans which is a ... in order to reach the "command center" of the cell,s ...
... 2012) -- A rat may never be man,s best ... sponsored by scientists with the U.S. Army Research Laboratory, ... Counter Explosives Hazards Center, will determine if and how ... In July, Barron Associates Inc., Charlottesville, Va. was ...
... Xian Chang Li, MD, PhD, Brigham and Women,s Hospital (BWH) ... of lymphocytes, called CD4+ T cells, mature into various subsets ... that a particular cell surface molecule, known as OX40, is ... copious amounts of interleukin-9 (IL-9) (and therefore called TH9 cells) ...
Cached Biology News:Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 3RATS research may teach rodents to detect explosives 2Cell receptor has proclivity for T helper 9 cells, airway inflammation 2
... the template-directed polymerization of nucleotides into duplex ... I possesses a 3?5 exonuclease activity or ... during DNA replication, and also contains a ... to replace nucleotides in the growing strand ...
Request Info...
supplied with 10x reaction buffer...
... ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: NADP ... of HK will phosphorylate 1 ... min at 25C at pH ... will oxidize 1 mol of ...
Biology Products: